2 boys' deaths halt S.F. company's rare disease gene therapy trial

Two boys died in a critical gene therapy trial against a genetic disease, forcing the company behind the therapy and regulators to halt the study. Audentes Therapeutics Inc., a San Francisco company that was sold in January to Astellas Pharma of Japan for $3 billion, said both boys with X-linked myotubular myopathy had been given a higher dose of the therapy and had pre-existing liver problems. The news comes as gene therapies face question s as well as a pivotal moment. BioMarin Pharmaceutical…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news